Pregnenolone succinate
| Clinical data | |
|---|---|
| Trade names | Panzalone, Formula 405 |
| Other names | Pregnenolone hemisuccinate; Pregn-5-en-3β-ol-20-one 3β-(hydrogen succinate) |
| Routes of administration |
Topical |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.022.728 |
| Chemical and physical data | |
| Formula | C25H36O5 |
| Molar mass | 416.558 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pregnenolone succinate (USAN; brand names Panzalone, Formula 405; also known as pregnenolone hemisuccinate or pregn-5-en-3β-ol-20-one 3β-(hydrogen succinate)) is a synthetic pregnane steroid and an ester of pregnenolone which is described as a glucocorticoid and anti-inflammatory drug and has been patented and marketed as a topical medication in the form of a cream for the treatment of allergic, pruritic, and inflammatory dermatitis. It has also been described as a non-hormonal sterol, having neurosteroid activity, and forming a progesterone analogue via dehydrogenation.
In addition to its glucocorticoid effects, pregnenolone succinate has been found to act as a negative allosteric modulator of the GABAA receptor and a positive allosteric modulator of the NMDA receptor similarly to pregnenolone sulfate.
See also
| Glucocorticoids |
|
||||
|---|---|---|---|---|---|
| Antiglucocorticoids |
|
||||
| Synthesis modifiers | |||||
| |||||
| Ionotropic |
|
||||
|---|---|---|---|---|---|
| Metabotropic |
|
||||
| |||||||||||||||||||||||||||||||||||||